NCT05770375View on ClinicalTrials.gov

Tolerability of MDMA in Schizophrenia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Schizophrenia

Interventions

DRUG

MDMA 40mg

MDMA 40mg

DRUG

MDMA 80mg

MDMA 80mg

DRUG

MDMA 120mg

MDMA 120mg

Trial Locations (1)

90025

RECRUITING

UCLA, Los Angeles

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

lead

Anya Bershad, MD, PhD

OTHER